ITHERA MEDICAL GMBH

Their core work

iThera Medical is a Munich-based medical device company specializing in optoacoustic (photoacoustic) imaging systems for biomedical research and clinical diagnostics. They develop hardware and software for non-invasive, label-free visualization of tissue structure and function — from skin microvasculature to deep-tissue organ imaging. Their instruments are used across preclinical and clinical settings, enabling researchers and clinicians to monitor disease progression, track cell therapies, and guide surgical procedures without ionizing radiation. They bridge the gap between laboratory imaging research and deployable medical devices.

What they specialise in

How they've shifted over time

In their earlier projects (2015–2017), iThera Medical contributed optoacoustic imaging as one modality among many — working on surgical guidance (PRISAR), diabetes and islet transplantation imaging (iNanoBIT), and broad bio-photonic platforms (FBI). The emphasis was on proving their technology across diverse biomedical applications. From 2018 onward, their focus sharpened considerably toward raster-scan optoacoustic mesoscopy (RSOM) for specific clinical use cases — skin diagnostics (INNODERM, WINTHER), therapeutic monitoring, and handheld device formats. This shift signals a company moving from technology validation to clinical translation and product-market fit.

iThera Medical is moving from being an imaging technology provider for research labs toward delivering handheld, label-free clinical devices — particularly for dermatology and therapeutic monitoring applications.

How they like to work

iThera Medical primarily joins consortia as a specialist technology partner (7 of 8 projects as participant), bringing their proprietary optoacoustic imaging systems into multi-disciplinary teams. They coordinated one project (EUPHORIA, their largest single grant at EUR 1.16M), demonstrating they can lead when the project centers on their core technology. With 55 unique partners across 14 countries, they maintain a broad but non-repetitive network — typical of a technology SME that adapts its instruments to different research domains rather than relying on a fixed set of collaborators.

iThera Medical has collaborated with 55 distinct partners across 14 countries, indicating a well-connected European network. Their partnerships span universities, hospitals, and research institutes working in medical imaging, regenerative medicine, and nanotechnology — concentrated in Western and Central Europe.

What sets them apart

iThera Medical is one of very few companies worldwide that manufactures commercial optoacoustic imaging systems, giving them a rare position as both a technology developer and an industrial partner who can supply actual devices to research consortia. Unlike academic imaging labs, they bring product engineering, manufacturing capability, and regulatory awareness to projects. For consortium builders, they offer a turnkey imaging solution that can be customized to specific biomedical applications — from dermatology to transplant monitoring — without needing to build imaging hardware from scratch.

Highlights from their portfolio

• EUPHORIA
  Their only coordinator role and largest single grant (EUR 1.16M) — focused on combining ultrasound and photoacoustic imaging for intestinal diagnostics, representing their strongest commitment to a clinical application.
• WINTHER
  Largest total funding as participant (EUR 947K) and most recent project, developing handheld RSOM for therapeutic monitoring — signals the company's current product direction.
• iNanoBIT
  Longest-running project (2017–2023) integrating optoacoustics with five other imaging modalities for diabetes cell therapy, showcasing the widest multimodal capability.